Replies to post #263771 on Amarin Corp Plc (AMRN)

[Number sleven]

Kiwi, thanks for getting back to me. Backing Teva in the US would make sense in the event of losing the appeal. Royalty payments are better than nothing. I would think we could also amend our settlement agreement with Teva to get them to market possible ahead of the generics we are in court with. Winning the court battle in this situation is not the point. ( in my opinion.) Money is the point. Backing Teva would be one more way we could stop the other generic companies from making money. If we can see this then I assume all the lawyers involved can see this. This situation is very different then our FDA battle from year's ago. Amarin and the generic companies both have something to gain by reaching an agreement, and everything to loose by fighting. I have been invested here since before the original adcom. Reading your posts ever since. Nice to actually talk to you.
Sleven.

[hamkypamky]

Rather than having a fragmented market between several generic Co's ...AMRN would help Teva dominate ..and get royalties . Just looking at all possibilities ...still want AMRN to win the appeal obviously

There's a big flaw in this argument, which is how exactly will AMRN "help TEVA dominate" unless they already own all the supply (which we agreed they don't).

AMRN wont advertise on behalf of TEVA (because margins from the royalties are presumably low enough that they would swallow any profit from ad spends).
TEVA has higher cost (they have to pay royalties, H&R don't).
Any other generic can come into this space (as they have done for GL). And there are many generics with a lower cost base / hungrier than TEVA and willing to sacrifice margins. Generic market is all about $.

Yes something is "better" than nothing. But the market will still likely be fragmented. Even if TEVA takes the lion share (50%) of the market due to logistics, it still won't be worth AMRN's while to expand the market for measly royalties from that 50%.